Drug repurposing for cancer therapy
Open accessThe DOI matches its Crossref record; 508 of the 513 references it cites were found in a registry or an index; 127 of the 249 sources its claims cite were checked for support.
Abstract
Comprehensive review of methods and candidate repurposed drugs for cancer therapy.
Overview
CoChat Summary
## TL;DR
This is a narrative review of drug repurposing for cancer therapy, summarizing experimental and computational strategies, hallmark-targeting examples, tumor microenvironment targets, and nanomaterial-based delivery. It argues that repurposed drugs may speed development and reduce cost, but clinical translation remains limited by bioavailability, dosing, toxicity, and regulatory barriers.
## Key findings
- The review organizes drug repurposing around the 14 hallmarks of cancer and the tumor microenvironment (TME), and notes that repurposed drugs may target multiple malignancy features and support combination therapy.
- It states that conventional drug development can take 10–15 years and cost $1–2 billion, whereas repurposing is faster and cheaper because existing drugs already have known safety, dosage, and toxicity profiles.
- The paper highlights several reported quantitative findings from prior studies, including a 45% risk reduction in thyroid cancer among metformin users in Eastern countries, and lower gynecological cancer occurrence with metformin: HR = 0.60 (95% CI: 0.49–0.74), endometrial cancer HR = 0.65 (95% CI: 0.50–0.85), and ovarian cancer HR = 0.47 (95% CI: 0.27–0.82).
- It also cites a phase I clinical trial of leflunomide in refractory multiple myeloma where disease stabilization occurred in 9 of 11 patients.
## Methods
- Design: Narrative review/systematic overview of published work on drug repurposing for cancer therapy, centered on hallmarks of cancer, TME-targeting therapy, and nanomaterial-based delivery.
- Data/sample: The text does not report a primary study sample; instead, it synthesizes examples from preclinical studies, epidemiological analyses, and clinical trials, and mentions use of databases and tables of repurposed-drug candidates.
- Main analysis: The paper categorizes repurposing strategies into experimental approaches (including phenotypic screening and organoid/tumoroid models) and computational approaches (including molecular docking, network analysis, data mining, similarity analysis, machine learning, and transcriptional signature methods).
## Limitations
- The paper explicitly states that many repurposed drugs have not yet translated into clinical application, and that clinical trial evidence is limited for several TME-targeting candidates.
- It notes several practical barriers: bioavailability limits, instability, poor solubility, toxicity, dosing uncertainty, patent/IP issues, regulatory barriers, and limited funding for trials.
- The text also makes evident, but does not present as a formal limitation, that much of the evidence discussed is preclinical and often based on small or ongoing clinical studies rather than large randomized trials.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
99 Valid · 15 Not valid · 82 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Furthermore, TPL has been shown to induce autophagy-mediated caspase-independent cell death in tumor cells.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Inducing cell death
What the sources say
- Disputedcites [91] Zhao F Triptolide induces protective autophagy through activation of the CaMKKβ-AMPK signaling pathway in prostate cancer cells Oncotarget 2016 7 5366 5382 10.18632/oncotarget.6783 26734992 PMC4868692 sourceExperimental — accuracy not yet measured
The Results section (‘Triptolide induces cytoprotective autophagy in PCa cells’; page not supplied) concludes that autophagy protects prostate cancer cells from triptolide-induced death: inhibiting autophagy increased both cell death and caspase-3 cleavage. This is contrary to the attributed claim that triptolide-induced autophagy mediates caspase-independent cell death. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Celecoxib has been shown to enhance the efficacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κB pathway.”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Targeting tumor-promoting inflammation
What the sources say
- Disputedcites [183] Vergani E miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators Cell Commun. Signal 2020 18 156 10.1186/s12964-020-00601-1 32967672 PMC7510138 sourceExperimental — accuracy not yet measured
The Results section (“Targeting COX2 restores melanoma sensitivity to BRAF/MEKi”; page unavailable) supports increased growth inhibition and cytotoxicity with celecoxib plus BRAF/MEKi in melanoma cells. But it reports noncanonical NF-κB activation, not suppression, and attributes the enhanced apoptotic effects to reduced PGE2 production. The Discussion likewise describes activation of NF-κB signaling cascades during celecoxib-induced cell death. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Dong and colleagues reported the nuanced relationship between EGCG and the WNT/β-catenin signaling pathway by demonstrating that overexpression of β-catenin could either augment or reduce the anticancer effects of EGCG.147”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Interfering with replication
What the sources say
- Disputedcites [147] Dong C Epigallocatechin-3-gallate suppresses the growth of human osteosarcoma by inhibiting the Wnt/β-catenin signalling pathway Bioengineered 2022 13 8490 8502 10.1080/21655979.2022.2051805 35348430 PMC9161922 sourceExperimental — accuracy not yet measured
In “EGCG inhibits OS growth by regulating the Wnt/β-catenin pathway” (Figure 4c–f; page not supplied), the paper reports that β-catenin overexpression inhibited EGCG’s antitumour and pro-apoptotic effects. It was β-catenin knockdown, not overexpression, that strengthened those effects. (LLM, conf=0.91)
Checked by a reasoning model — may be wrong.
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Another extensive meta-analysis ascertained a notably lower gynecological cancer occurrence in those undergoing metformin treatment compared to alternative therapies (gynecological cancer: HR = 0.60, 95% CI: 0.49–0.74; endometrial cancer: HR = 0.65, 95% CI: 0.50–0.85; ovarian cancer: HR = 0.47, 95% CI: 0.27–0.82).203”
§ Drug repurposing for cancer therapy > Drug repurposing: candidates for the therapeutic targeting of hallmarks of cancer > Locking phenotypic plasticity
What the sources say
- Disputedcites [203] Yao K Zheng H Li T Association between metformin use and the risk, prognosis of gynecologic cancer Front. Oncol. 2022 12 942380 10.3389/fonc.2022.942380 35898873 PMC9309370 sourceExperimental — accuracy not yet measured
The Discussion section on cancer risk (page not provided) reports no significant association between metformin use and the occurrence of gynecological, endometrial, or ovarian cancer in women with diabetes. The cited hazard ratios appear instead in the Discussion section on prognosis, where they describe overall survival among patients with cancer, not cancer occurrence. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Notably, high-throughput screening using sophisticated models can identify compounds that mitigate disease symptoms without necessitating pre-existing knowledge about the drug-target interactions.29,30”
§ Drug repurposing for cancer therapy > Drug repurposing strategies
What the sources say
- Partly supportedcites [29] Huang H Zhang P Qu XA Sanseau P Yang L Systematic prediction of drug combinations based on clinical side-effects Sci. Rep. 2014 4 7160 10.1038/srep07160 25418113 PMC4241517 sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) describes a computational model that uses clinical side effects to predict drug combinations, rather than requiring drug-target interaction data. But it does not show that the predicted compounds mitigate disease symptoms; the Discussion (page unavailable) says the predictions need experimental testing. The Abstract also distinguishes this approach from high-throughput screening, which it says is impractical for all possible combinations. (LLM, conf=0.86)
- Could not verifycites [30] Kuhn M Campillos M Letunic I Jensen LJ Bork P A side effect resource to capture phenotypic effects of drugs Mol. Syst. Biol. 2010 6 343 10.1038/msb.2009.98 20087340 PMC2824526 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) discusses databases of cellular phenotypes and the potential of large-scale computational methods; it does not describe screening sophisticated models to find compounds that relieve disease symptoms. Searches for high-throughput screening, symptom mitigation, and drug-target-independent screening found no passage addressing that claim. (LLM, conf=0.73)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
113 more claims · 51 with their cited sources checked
Create a free account to see all 223 claims and to verify the 21 references still open.
- It may state two separate claims as one. 87
- Probably not a substantial claim. 25
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“134 Ongoing clinical trials are currently examining the ef fi cacy of simvastatin against various cancers, including breast (NCT00807950, NCT05550415), gastric (NCT01099085, NCT03086291), colorectal (NCT01238094), and bladder (NCT02360618) cancer.”
Cited work 10.1038/cddis.2017.46 · retracted 2025-11-27 · notice 10.1038/s41419-025-08275-8 · this paper published 2024-04-19
Citations
Cites
1 retracted
Items 201–400 of 508
Immunomodulatory effects of inulin and its intestinal metabolites
Sheng, W., Ji, G., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1224092 · Cited by 170 · cited 1×
“Inulin (C 17 H 19 NO 3 ), a quintessential soluble dietary fi ber predominantly sourced from plants such as chicory, ginger, garlic, onion, and asparagus, 221 has emerged as a multifaceted ingredient in the culinary and pharmaceutical sectors.”
BackgroundCelastrol as an emerging anticancer agent: Current status, challenges and therapeutic strategies
Wang, C., Dai, S., Zhao, X., Zhang, Y., Gong, L., Fu, K., Ma, C., Peng, C. Y., & Li, Y. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114882 · Cited by 170 · cited 1×
“355,356 To circumvent these challenges, Ding et al. innovatively encapsulated celastrol into SF nanoparticles (CL-SFNPs) using a modi fi ed desolvation method and found that CL-SFNPs outperformed free-form celastrol in terms of antitumor ef fi cacy, inhibition of colony formation, and induction of…”
MethodDeMaria, P. J., & Bilušić, M. (2019) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.12.001 · Cited by 168 · cited 1×
“262 Thus, vaccines pose a promising approach to target the TIME in cancer treatment.”
BackgroundDrug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Würth, R., Thellung, S., Bajetto, A., Mazzanti, M., Florio, T., & Barbieri, F. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.09.017 · Cited by 167
Polymeric Micelles for Multi-Drug Delivery in Cancer
Cho, H., Lai, T. C., Tomoda, K., & Kwon, G. S. (2015) · AAPS PharmSciTech · doi:10.1208/s12249-014-0251-3 · Cited by 159 · cited 1×
“358,359 363 Thus, PMs could act as potential carriers for repurposed drugs.”
BackgroundThe mechanical microenvironment in cancer: How physics affects tumours
Nagelkerke, A., Bussink, J., Rowan, A. E., & Span, P. N. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.09.001 · Cited by 158 · cited 1×
“278,279 The formation of a mechanical microenvironment primarily depends on collagen and fi brin, integrins and fi broblasts.”
BackgroundRB: mitotic implications of a tumour suppressor
Manning, A. L., & Dyson, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3216 · Cited by 157
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide
Mattar, T., Kochhar, K., Bartlett, R., Bremer, E. G., & Finnegan, A. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81704-4 · Cited by 155
Design of efficient computational workflows for in silico drug repurposing
Vanhaelen, Q., Mamoshina, P., Aliper, A. M., Artemov, A., Lezhnina, K., Ozerov, I., Labat, I., & Zhavoronkov, A. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2016.09.019 · Cited by 150
Randomized, Placebo-Controlled Trial of Green Tea Catechins for Prostate Cancer Prevention
Kumar, N. B., Pow‐Sang, J. M., Egan, K. M., Spiess, P. E., Dickinson, S. I., Salup, R. R., Helal, M. A., McLarty, J. W., WILLIAMS, C. R., Schreiber, F. J., et al. (2015) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0324 · Cited by 147
Immunosuppressive, anti-inflammatory and anti-cancer properties of triptolide: A mini review.
(2016) · PubMed Central · Cited by 147
Guerini, A. E., Triggiani, L., Maddalo, M., Bonù, M. L., Frassine, F., Baiguini, A., Alghisi, A., Tomasini, D., Borghetti, P., Pasinetti, N., et al. (2019) · Cancers · doi:10.3390/cancers11091284 · Cited by 146
Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment
Hundley, W. G., D’Agostino, R., Crotts, T., Craver, K., Hackney, M. H., Jordan, J. H., Ky, B., Wagner, L. I., Herrington, D. M., Yeboah, J., et al. (2022) · NEJM Evidence · doi:10.1056/evidoa2200097 · Cited by 143
Huang, J., Chaudhary, R. T., Cohen, A. L., Fink, K., Goldlust, S. A., Boockvar, J. A., Chinnaiyan, P., Wan, L., Marcus, S. G., & Campian, J. L. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03125-y · Cited by 142
Pillaiyar, T., Meenakshisundaram, S., Manickam, M., & Sankaranarayanan, M. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112275 · Cited by 140 · cited 1×
“24 Historically, drug repurposing in oncology has largely been driven by either an understanding of the disease pathways or through serendipitous fi ndings.”
BackgroundMathur, D., Stratikopoulos, E., Ozturk, S., Steinbach, N., Pegno, S., Schoenfeld, S., Yong, R., Murty, V. V., Asara, J. M., Cantley, L. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0612 · Cited by 139 · cited 1×
“105,106 In addition, Yamaguchi and colleagues proposed that le fl unomide-mediated pyrimidine synthesis could be a therapeutic target for mitigating the metastatic progression of CRC.”
BackgroundLadson, G., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Williams, N. I., Coney, P., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.12.002 · Cited by 138
Mandal, C. C., Ghosh-Choudhury, N., Yoneda, T., Choudhury, G. G., & Ghosh-Choudhury, N. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.193714 · Cited by 138 · cited 1×
“132 In parallel studies, Miyajima and colleagues found that simvastatin and fl uvastatin activated the transcriptional function of P53 by suppressing TAZ protein expression.”
BackgroundLuo, K.-W., Chen, W., Lung, W.-Y., Wei, X.-Y., Cheng, B.-H., Cai, Z.-M., & Huang, W.-R. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.12.004 · Cited by 137
Stabilization of p53 Is Involved in Quercetin-Induced Cell Cycle Arrest and Apoptosis in HepG2 Cells
TANIGAWA, S., FUJII, M., & HOU, D.-X. (2008) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.70680 · Cited by 135 · cited 1×
“239 Thus, quercetin stands out as a potent tool to induce senescence in cancer cells.”
BackgroundPatient-derived organoid models help define personalized management of gastrointestinal cancer
Aberle, M. R., Burkhart, R. A., Tiriac, H., Olde Damink, S. W. M., Dejong, C. H. C., Tuveson, D. A., & van Dam, R. M. (2018) · British Journal of Surgery · doi:10.1002/bjs.10726 · Cited by 135
Leflunomide: A Review of its Use in Active Rheumatoid Arthritis
Prakash, A., & Jarvis, B. (1999) · Drugs · doi:10.2165/00003495-199958060-00010 · Cited by 135
Pintova, S., Dharmupari, S., Moshier, E. L., Zubizarreta, N. J., Ang, C., & Holcombe, R. F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03886-3 · Cited by 134
Kanazawa, T., Morisaki, K., Suzuki, S., & Takashima, Y. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400644e · Cited by 132
Drug databases and their contributions to drug repurposing
Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M., & Masoudi-Nejad, A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.06.021 · Cited by 131
Exploration of databases and methods supporting drug repurposing: a comprehensive survey
Tanoli, Z., Seemab, U., Scherer, A., Wennerberg, K., Tang, J., & Vähä-Koskela, M. (2021) · Briefings in Bioinformatics · doi:10.1093/bib/bbaa003 · Cited by 131 · cited 1×
“27,28 More often, these techniques are synergistically utilized.”
MethodThe Gut Microbiome in Pancreatic Disease
Akshintala, V. S., Talukdar, R., Singh, V. K., & Goggins, M. (2019) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.045 · Cited by 131 · cited 1×
“215,216 Intriguingly, although many of these microorganisms play benign or even bene fi cial roles, some can also contribute to disease progression, including cancers.”
BackgroundThe Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs
Son, D.-S., Lee, E.-S., & Adunyah, S. E. (2020) · Immune Network · doi:10.4110/in.2020.20.e29 · Cited by 130
Jo, U., Senatorov, I. S., Zimmermann, A., Saha, L. K., Murai, Y., Kim, S. H., Rajapakse, V. N., Elloumi, F., Takahashi, N., Schultz, C. W., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-1026 · Cited by 128
Moradzadeh, M., Hosseini, A., Erfanian, S., & Rezaei, H. (2017) · Pharmacological Reports · doi:10.1016/j.pharep.2017.04.008 · Cited by 127 · cited 1×
“146 Recently, Dong and colleagues reported the nuanced relationship between EGCG and the WNT/ β -catenin signaling pathway by demonstrating that overexpression of β -catenin could either augment or reduce the anticancer effects of EGCG.”
BackgroundNanoliposomes in Cancer Therapy: Marketed Products and Current Clinical Trials
Taléns-Visconti, R., Díez-Sales, O., de Julián-Ortiz, J. V., & Nácher, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084249 · Cited by 127 · cited 1×
“365 Niclosamide (NIC), recognized as an anthelmintic drug for over 50 years, also serves as an effective inhibitor of STAT3.”
BackgroundWang, J., Man, G. C. W., Chan, T. H., Kwong, J., & Wang, C. C. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.09.054 · Cited by 127
Coombs, M. R. P., Harrison, M. E., & Hoskin, D. W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.023 · Cited by 126 · cited 1×
“259,260 These fi ndings highlight the intertwined relationship between T cell activation, apigenin-dependent PD-L1 regulation, and subsequent cancer cell demise.”
BackgroundKasagi, Y., Chandramouleeswaran, P. M., Whelan, K. A., Tanaka, K., Giroux, V., Sharma, M., Wang, J., Benitez, A., DeMarshall, M., Tobias, J. W., et al. (2018) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.12.013 · Cited by 126 · cited 1×
“37,38 Such models have adeptly mirrored the feasibility of tumoroids in the accurate recapitulation of KRAS-mutant metastatic rectal cancer with microsatellite stability after hepatic resection and treatment with neoadjuvant combination chemotherapies in colorectal cancer (CRC), 39 as well as…”
MethodTargeting regulated cell death in tumor nanomedicines
Zeng, Q., Ma, X., Song, Y., Chen, Q., Jiao, Q., & Zhou, L. (2021) · Theranostics · doi:10.7150/thno.67932 · Cited by 125
Zhao, L., Liu, Y., Zhang, S., Wei, L., Cheng, H., Wang, J., & Wang, J. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04821-w · Cited by 125 · cited 1×
“246,247 The TME supports the survival and migration of cancer cells throughout the organism in response to internal or external stimuli, including treatments.”
BackgroundResearch Progress, Challenges, and Breakthroughs of Organoids as Disease Models
Huang, Y., Huang, Z., Tang, Z., Chen, Y., Huang, M., Liu, H., Huang, W., Ye, Q., & Jia, B. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.740574 · Cited by 124
Cruz-Correa, M., Hylind, L. M., Marrero, J. H., Zahurak, M. L., Murray-Stewart, T., Casero, R. A., Montgomery, E. A., Iacobuzio-Donahue, C., Brosens, L. A., Offerhaus, G. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.031 · Cited by 123
In-silico Prediction of Synergistic Anti-Cancer Drug Combinations Using Multi-omics Data
Celebi, R., Bear Don’t Walk, O., Movva, R., Alpsoy, S., & Dumontier, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45236-6 · Cited by 120 · cited 1×
“27,31,32 In summary, although the idea of drug repurposing is long-established, it is only recently that technological advances, such as the ones outlined in this article, have led to the development of cutting-edge strategies that can be consciously paired with novel indications.”
BackgroundNitric oxide and its derivatives in the cancer battlefield
Kamm, A., Przychodzen, P., Kuban-Jankowska, A., Jacewicz, D., Dabrowska, A. M., Nussberger, S., Wozniak, M., & Gorska-Ponikowska, M. (2019) · Nitric Oxide · doi:10.1016/j.niox.2019.09.005 · Cited by 120
Selective Induction of Apoptosis with Proton Pump Inhibitor in Gastric Cancer Cells
Yeo, M., Kim, D.-K., Kim, Y.-B., Oh, T. Y., Lee, J.-E., Cho, S. W., Kim, H. C., & Hahm, K.-B. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1065 · Cited by 120 · cited 1×
“311 Similar fi ndings have been reported in other in vitro studies, indicating that potential downstream effectors, such as the dephosphorylation of low-density lipoprotein receptor-related protein 6 and the inhibition of WNT/ β -catenin 312 or PI3K/AKT/mTOR/HIF-1 α signaling pathways, 313 follow…”
BackgroundHNF4α is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer
Chang, H. R., Nam, S., Kook, M.-C., Kim, K.-T., Liu, X., Yao, H., Jung, H. R., Lemos, R., Seo, H. H., Park, H. S., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-307918 · Cited by 119 · cited 1×
“199 A different study reported that metformin inhibited HNF4G activity via AMPK-driven phosphorylation and ubiquitin-mediated degradation, which suppressed the invasive abilities and metastasis of SMAD4-de fi cient pancreatic ductal adenocarcinoma cells.”
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 118
Polymeric micelles as mighty nanocarriers for cancer gene therapy: a review
Yousefpour Marzbali, M., & Yari Khosroushahi, A. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3273-1 · Cited by 115 · cited 1×
“358,359 363 Thus, PMs could act as potential carriers for repurposed drugs.”
BackgroundFlavones from Root of Scutellaria Baicalensis Georgi: Drugs of the Future in Neurodegeneration?
Gąsiorowski, K., Lamer-Zarawska, E., Leszek, J., Parvathaneni, K., Yendluri, B. B., BŁACH-OLSZEWSKA, Z., & Aliev, G. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711794480384 · Cited by 114 · cited 1×
“207,208 More recently, a role for BE in non-mutational epigenetic regulation has been described.”
BackgroundRepurposing approved drugs on the pathway to novel therapies
Schein, C. H. (2020) · Medicinal Research Reviews · doi:10.1002/med.21627 · Cited by 109 · cited 1×
“376 This shift could lead to unexpected binding to off-target molecules, and the introduction of unforeseen side effects when the drug is administered to humans.”
BackgroundPimentel, I., Lohmann, A. E., Ennis, M., Dowling, R. J. O., Cescon, D. W., Elser, C., Potvin, K., Haq, R., Hamm, C. M., Chang, M. C., et al. (2019) · The Breast · doi:10.1016/j.breast.2019.08.003 · Cited by 108
Zhou, Z., Van der Jeught, K., Fang, Y., Yu, T., Li, Y., Ao, Z., Liu, S., Zhang, L., Yang, Y., Eyvani, H., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00805-x · Cited by 107 · cited 1×
“44 In addition, the drug atorvastatin was found to inhibit angiogenesis in a dose-dependent manner through the downregulation of vascular endothelial growth factor (VEGF), CD31, and Bcl-2 in a co-culture of glioblastoma organoids and human umbilical vein endothelial cells in fi brin gels, indicating…”
BackgroundJi, Y., Chen, S., Yang, K., Zhang, X., Zhou, J., Li, L., Xiang, B., Qiu, T., Dai, S., Jiang, X. L., et al. (2021) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2021.0454 · Cited by 106
The Innovative Potential of Statins in Cancer: New Targets for New Therapies
Di Bello, E., Zwergel, C., Mai, A., & Valente, S. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.00516 · Cited by 105 · cited 1×
“130,131 Of the statins, simvastatin is particularly interesting due to its anticancer applications, which have been observed in various cancer types and are largely mediated through activation of mutant P53.”
BackgroundLynch, P. M., Burke, C. A., Phillips, R., Morris, J. S., Slack, R., Wang, X., Liu, J., Patterson, S., Sinicrope, F. A., Rodriguez-Bigas, M. A., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-307235 · Cited by 104
Wang, S., He, H., Chen, L., Zhang, W., Zhang, X., & Chen, J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8755-0 · Cited by 104
Lipid metabolism reprogramming in tumor-associated macrophages and implications for therapy
Qiao, X., Hu, Z., Xiong, F., Yang, Y., Peng, C., Wang, D., & Li, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01807-1 · Cited by 103 · cited 1×
“For instance, many types of cancers display dysregulation in cell metabolism, 389,390 and impaired apoptotic pathways.”
BackgroundCatecholamines contribute to the neovascularization of lung cancer via tumor-associated macrophages
Xia, Y., Wei, Y., Li, Z.-Y., Cai, X.-Y., Zhang, L.-L., Dong, X.-R., Zhang, S., Zhang, R.-G., Meng, R., Zhu, F., et al. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2019.06.004 · Cited by 103 · cited 1×
“326,327 This catecholamine-driven effect was found to be mitigated by the β -AR antagonist, propranolol.”
BackgroundSelf-citationMessing, E. M., Gee, J., Saltzstein, D. R., Kim, K., di Sant'Agnese, A., Kolesar, J., Harris, L. S., Faerber, A. E., Havighurst, T. C., Young, J. M., et al. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0455 · Cited by 102
Randomized placebo-controlled study of lovastatin in children with neurofibromatosis type 1
Payne, J. M., Barton, B., Ullrich, N. J., Cantor, A., Hearps, S. J. C., Cutter, G., Rosser, T., Walsh, K. S., Gioia, G. A., Wolters, P. L., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003435 · Cited by 102
β-blockers: Their new life from hypertension to cancer and migraine
Fumagalli, C., Maurizi, N., Marchionni, N., & Fornasari, D. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104587 · Cited by 102 · cited 1×
“326,327 This catecholamine-driven effect was found to be mitigated by the β -AR antagonist, propranolol.”
BackgroundIdentifying Network of Drug Mode of Action by Gene Expression Profiling
Iorio, F., Tagliaferri, R., & Bernardo, D. D. (2009) · Journal of Computational Biology · doi:10.1089/cmb.2008.10tt · Cited by 101
Tai, L.-H., Alkayyal, A. A., Leslie, A. L., Sahi, S., Bennett, S., Tanese de Souza, C., Baxter, K., Angka, L., Xu, R., Kennedy, M. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1431082 · Cited by 101 · cited 1×
“266 Currently, multiple infectious disease vaccines are the focus of oncology-based preclinical and clinical trials.”
BackgroundLiao, J.-F., Chiou, W.-F., Shen, Y.-C., Wang, G.-J., & Chen, C.-F. (2011) · Chinese Medicine · doi:10.1186/1749-8546-6-6 · Cited by 100 · cited 1×
“338 Beyond its traditional medicinal applications, EVO is also a popular dietary supplement.”
BackgroundNiclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities
Barbosa, E. J., Löbenberg, R., de Araújo, G. L. B., & Bou‐Chacra, N. A. (2019) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2019.05.004 · Cited by 100 · cited 1×
“366,367 However, the clinical application of NIC has been constrained due to its poor water solubility and bioavailability.”
BackgroundA comprehensive overview of Artemisinin and its derivatives as anticancer agents
Zeng, Z.-W., Chen, D., Chen, L., He, B., & Li, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115000 · Cited by 97
Dacha, S., Razvi, M., Massaad, J., Cai, Q., & Wehbi, M. (2015) · Gastroenterology Report · doi:10.1093/gastro/gov004 · Cited by 97
Peppicelli, S., Bianchini, F., Torre, E., & Calorini, L. (2014) · Clinical & Experimental Metastasis · doi:10.1007/s10585-014-9637-6 · Cited by 97 · cited 1×
“306 In addition, the functionality of antitumor agents, such as T cells and NK cells, is often reduced under acidic conditions.”
BackgroundLi, J., Lei, K., Wu, Z., Li, W., Liu, G., Liu, J., Cheng, F., & Tang, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.10052 · Cited by 97
Kim, Y.-S., Lee, Y.-M., Oh, T.-I., Shin, D. H., Kim, G.-H., Kan, S.-Y., Kang, H., Kim, J. H., Kim, B. M., Yim, W. J., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19103127 · Cited by 97 · cited 1×
“274 Similarly, other studies have demonstrated that emodin regulates SREBP1 leading to a reduction in triglyceride levels and fatty acid desaturation, and ultimately inducing apoptosis in liver cancer cells.”
BackgroundChen, X., Liu, J., Gu, X., & Ding, F. (2008) · Brain Research · doi:10.1016/j.brainres.2008.07.051 · Cited by 96
Elkind-Hirsch, K. E., Chappell, N., Seidemann, E., Storment, J., & Bellanger, D. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab408 · Cited by 96
Repurposing old drugs to fight multidrug resistant cancers
Dinić, J., Efferth, T., García-Sosa, A. T., Grahovac, J., Padrón, J. M., Pajeva, I., Rizzolio, F., Saponara, S., Spengler, G., & Tsakovska, I. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100713 · Cited by 95 · cited 1×
“366,367 However, the clinical application of NIC has been constrained due to its poor water solubility and bioavailability.”
BackgroundCellular senescence in cancer: clinical detection and prognostic implications
Domen, A., Deben, C., Verswyvel, J., Flieswasser, T., Prenen, H., Peeters, M., Lardon, F., & Wouters, A. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02555-3 · Cited by 94
Mebendazole in enterobiasis. Radiochemical and pilot clinical study in 1,278 subjects.
Brugmans, J. P., Thienpont, D., van Wijngaarden, I., et al. (1971) · PubMed · Cited by 93
Shen, X., Li, T., Xie, X., Feng, Y., Chen, Z., Yang, H., Wu, C., Deng, S., & Liu, Y. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.00381 · Cited by 92 · cited 1×
“350,351 This adaptability is particularly impactful when encapsulating drugs and elevating their targeted delivery, especially in oncology.”
BackgroundTransforming medicine with the microbiome
Zmora, N., Soffer, E., & Elinav, E. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1815 · Cited by 92
Fang, J., Wu, Z., Cai, C., Wang, Q., Tang, Y., & Cheng, F. (2017) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00216 · Cited by 92
New drugs are not enough‑drug repositioning in oncology: An update
Armando, R., Mengual G�mez, D., & Gomez, D. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.4966 · Cited by 90
Kitzen, J. J. E. M., de Jonge, M. J. A., Lamers, C. H. J., Eskens, F. A. L. M., van der Biessen, D., van Doorn, L., ter Steeg, J., Brandely, M., Puozzo, C., & Verweij, J. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.026 · Cited by 89
Pernicova, I., Kelly, S., Ajodha, S., Sahdev, A., Bestwick, J. P., Gabrovska, P., Akanle, O., Ajjan, R., Kola, B., Stadler, M., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30021-8 · Cited by 89
Clinical therapies and nano drug delivery systems for urinary bladder cancer
Jain, P., Kathuria, H., & Momin, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107871 · Cited by 89 · cited 2×
“364 Their inherent ability to transport both hydrophobic and hydrophilic agents, 347 combined with their ease of synthesis, extensive surface area, and adaptability for targeted modi fi cations, positions them as a pivotal vehicle for drug delivery.”
BackgroundInnovations in natural ingredients and their use in skin care.
Fowler, J. F., Woolery-Lloyd, H. C., Waldorf, H. A., & Saini, R. (2010) · PubMed · Cited by 88
Epidrug Repurposing: Discovering New Faces of Old Acquaintances in Cancer Therapy
Montalvo-Casimiro, M., González‐Barrios, R., Meraz-Rodríguez, M. A., Juárez-González, V. T., Arriaga-Canon, C., & Herrera, L. A. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.605386 · Cited by 88
Yu, C., Jiao, Y., Xue, J., Zhang, Q., Yang, H., Xing, L., Chen, G., Wu, J., Zhang, S., Zhu, W., et al. (2017) · International Journal of Biological Sciences · doi:10.7150/ijbs.18830 · Cited by 88
Lin, C.-Y., Chang, T.-W., Hsieh, W.-H., Hung, M.-C., Lin, I.-H., Lai, S.-C., & Tzeng, Y.-J. (2016) · Cell Death Discovery · doi:10.1038/cddiscovery.2016.65 · Cited by 88 · cited 1×
“96 Due to its multifaceted effects on cell death pathways, minimal resistance to its targets, and traditional use as a safe compound, Tanshinone IIA is emerging as a compelling candidate for anti-tumor therapies.”
BackgroundSacco, F., Silvestri, A., Posca, D., Pirro, S., Gherardini, P. F., Castagnoli, L., Mann, M., & Cesareni, G. (2016) · Cell Systems · doi:10.1016/j.cels.2016.02.005 · Cited by 88
Cai, J., Yi, M., Tan, Y., Li, X., Li, G., Zeng, Z., Xiong, W., & Xiang, B. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02100-8 · Cited by 87
Cholesterol and mevalonic acid modulation in cell metabolism and multiplication
Soma, M. R., Corsini, A., & Paoletti, R. (1992) · Toxicology Letters · doi:10.1016/0378-4274(92)90167-i · Cited by 87 · cited 1×
“392 – 395 However, the diversity of cancers is equally important.”
BackgroundDihydroartemisinin inhibits angiogenesis in pancreatic cancer by targeting the NF-κB pathway
Wang, S.-J., Sun, B., Cheng, Z.-X., Zhou, H.-X., Gao, Y., Kong, R., Chen, H., Jiang, H.-C., Pan, S.-H., Xue, D.-B., et al. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1643-7 · Cited by 86 · cited 1×
“152 In addition, DHA has been shown to trigger autophagy in HUVECs through suppression of the AKT/mTOR signaling pathway.”
BackgroundDrug repurposing for cancer therapy, easier said than done
González‐Fierro, A., & Dueñas‐González, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.012 · Cited by 85 · cited 1×
“374,375 It is our hope that such barriers can be overcome to fully realize the potential of drug repurposing.”
BackgroundCrist, M., Yaniv, B., Palackdharry, S. M., Lehn, M. A., Medvedovic, M., Stone, T. M., Gulati, S., Karivedu, V., Borchers, M. T., Fuhrman, B., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005632 · Cited by 85
Zhang, K., Bai, P., Dai, H., & Deng, Z. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.06.001 · Cited by 84
Establishment of patient-derived tumor spheroids for non-small cell lung cancer
Zhang, Z., Wang, H., Ding, Q., Xing, Y., Xu, Z., Lu, C., Luo, D., Xu, L., Xia, W., Zhou, C., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194016 · Cited by 84 · cited 1×
“36 With respect to gastrointestinal cancers, several investigations have harnessed PDOs as tools to evaluate drugs and identify potential therapeutic routes.”
BackgroundFu, L., Jin, W., Zhang, J., Zhu, L., Lu, J., Zhen, Y., Zhang, L., Ouyang, L., Liu, B., & Yu, H. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.006 · Cited by 83 · cited 1×
“13,397 In addition, the design and execution of clinical trials are crucial for drug repurposing strategies.”
BackgroundSelf-citationNygren, P., & Larsson, R. (2014) · Acta Oncologica · doi:10.3109/0284186x.2013.844359 · Cited by 83 · cited 1×
“164,165 Together, these fi ndings demonstrate the critical need to learn more about the therapeutic pro fi le of MBZ to ensure its safety in oncological applications and determine its ef fi cacy as a groundbreaking anticancer treatment.”
BackgroundDaponte, A., Ioannou, M., Mylonis, I., Simos, G., Minas, M., Messinis, I. E., & Koukoulis, G. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-335 · Cited by 82 · cited 1×
“296 Given these insights, targeting the hypoxic TME via drug repurposing may be bene fi cial in the development of oncological agents.”
BackgroundWang, C., Zhang, T., Liao, Q., Dai, M., Guo, J., Yang, X., Tan, W., Lin, D., Wu, C., & Zhao, Y. (2021) · Protein & Cell · doi:10.1007/s13238-020-00760-4 · Cited by 82 · cited 1×
“200 Intriguingly, metformin also appears to suppress the self-renewal capacities of CSCs, as evidenced by diminished expression of CSC markers (such as CD44 and CD133) and the growth of tumor spheroids through activation of AMP-activated protein kinase (AMPK) and inhibition of protein prenylation…”
BackgroundQuesada, A. R., Medina, M. Á., & Alba, E. (2007) · BioEssays · doi:10.1002/bies.20655 · Cited by 82 · cited 1×
“268,269 Endothelial cells are among the most studied stromal cells within the TME.”
BackgroundChen, Y., Zhang, J., Zhang, M., Song, Y., Zhang, Y., Fan, S., Ren, S., Fu, L., Zhang, N., Hui, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.577 · Cited by 82 · cited 1×
“209 From a molecular perspective, the 6-phosphogluconate dehydrogenase-driven oxidative pentose phosphate pathway is thought to facilitate the reshaping of histone H3K9 and DNA methylation patterns during tumor progression.”
BackgroundVaupel, P., & Multhoff, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01887 · Cited by 81
Nishikimi, M., Koshizaka, T., Ozawa, T., & Yagi, K. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90093-8 · Cited by 81 · cited 1×
“297,298 As an antioxidant, ascorbic acid protects against free radicals, and is involved in several vital physiological functions including collagen formation, wound healing, tissue repair, and maintaining the health of bones, cartilage, and teeth.”
BackgroundSMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium
Perekatt, A. O., Shah, P. P., Cheung, S., Jariwala, N., Wu, A., Gandhi, V., Kumar, N., Feng, Q., Patel, N., Chen, L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0043 · Cited by 80 · cited 1×
“187,188 Speci fi cally, SMAD4 can promote differentiation, thereby suppressing WNT-induced proliferation.”
BackgroundLawrence, K. S., Chau, T., & Engebrecht, J. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1005150 · Cited by 80 · cited 1×
“…events including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even as a consequence of genotoxic anticancer treatments, 169 is a crucial…”
BackgroundZeng, X., Liu, L., Zheng, M., Sun, H., Xiao, J., Lu, T., Huang, G., Chen, P., Zhang, J., Zhu, F., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7984 · Cited by 79
European Code against Cancer 4th Edition: Environment, occupation and cancer
Espina, C., Straíf, K., Friis, S., Kogevinas, M., Saracci, R., Vainio, H., & Schüz, J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.03.017 · Cited by 79
Kim, K. H., Choi, T. H., Choi, Y., Park, Y. W., Hong, K. Y., Kim, D., Choe, Y. S., Lee, H.-J., Cheon, J., Park, J., et al. (2017) · JAMA Dermatology · doi:10.1001/jamadermatol.2017.0250 · Cited by 79
Repurposing approved drugs for cancer therapy
Schein, C. H. (2021) · British Medical Bulletin · doi:10.1093/bmb/ldaa045 · Cited by 78 · cited 1×
“17 Similarly, thalidomide, despite its infamous history of causing severe birth defects, has been repurposed to treat conditions such as leprosy and multiple myeloma.”
BackgroundWei, R., Cortez Penso, N. E., Hackman, R. M., Wang, Y., & Mackenzie, G. G. (2019) · Nutrients · doi:10.3390/nu11081856 · Cited by 78
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78 · cited 1×
“18 In addition, arsenic trioxide (a poison) and all-trans retinoic acid (a metabolite of vitamin A) are examples of other chemical compounds 19 that were approved by the FDA in 2000 for the treatment of acute promyelocytic leukemia.”
BackgroundKim, S., Lee, H., Lee, S., Yoon, Y., & Choi, K.-H. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118800 · Cited by 78
Presurgical Trial of Metformin in Overweight and Obese Patients with Newly Diagnosed Breast Cancer
Kalinsky, K., Crew, K. D., Refice, S., Xiao, T., Wang, A., Feldman, S. M., Taback, B., Ahmad, A., Cremers, S., Hibshoosh, H., et al. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.889706 · Cited by 78
DvD: An R/Cytoscape pipeline for drug repurposing using public repositories of gene expression data
Pacini, C., Iorio, F., Gonçalves, E., Iskar, M., Klabunde, T., Bork, P., & Saez-Rodriguez, J. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts656 · Cited by 78
Metal Nanoparticles as Novel Agents for Lung Cancer Diagnosis and Therapy
Zheng, X., Wu, Y. K., Zuo, H., Chen, W., & Wang, K. (2023) · Small · doi:10.1002/smll.202206624 · Cited by 78 · cited 1×
“372 Among repurposed phyto-chemicals, ginsenoside is of interest to oncologists due to its potential tumor-suppressing properties.”
BackgroundZhao, F., Huang, W., Zhang, Z., Mao, L., Han, Y., Yan, J., & Lei, M. (2016) · Oncotarget · doi:10.18632/oncotarget.6783 · Cited by 77 · cited 1×
“91 Currently, a clinical trial has investigated the safety and anticancer ef fi cacy of the TPL derivative F60008 in patients with advanced solid tumors.”
BackgroundZhang, L., Kang, W., Lu, X., Ma, S., Dong, L., & Zou, B. (2018) · Gene · doi:10.1016/j.gene.2018.09.040 · Cited by 76
Penas-Prado, M., Hess, K. R., Fisch, M. J., Lagrone, L. W., Groves, M. D., Levin, V. A., De Groot, J. F., Puduvalli, V. K., Colman, H., Volas-Redd, G., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou155 · Cited by 76
Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives
Xu, C.-C., Deng, T., Fan, M.-L., Lv, W.-B., Liu, J.-H., & Yu, B.-Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.11.003 · Cited by 75 · cited 1×
“151 In addition, neither artemisinin nor DHA have shown substantial toxicity towards normal cells, highlighting their potential to act as suitable anticancer candidates.”
BackgroundFako, V. E., Wu, X., Pflug, B., Liu, J.-Y., & Zhang, J.-T. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501543u · Cited by 75
Tang, Y., Vater, C., Jacobi, A., Liebers, C., Zou, X., & Stiehler, M. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12611 · Cited by 74 · cited 1×
“78 Among these diverse effects, the ability of salidroside to act as an anticancer agent is of interest.”
BackgroundPhase II Trial of Concurrent Sunitinib and Image-Guided Radiotherapy for Oligometastases
Tong, C. C. L., Ko, E. C., Sung, M. W., Cesaretti, J. A., Stock, R. G., Packer, S. H., Forsythe, K., Genden, E. M., Schwartz, M., Lau, K. H. V., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0036979 · Cited by 74
Apigenin in cancer prevention and therapy: A systematic review and meta-analysis of animal models
Singh, D., Gupta, M., Sarwat, M., & Siddique, H. R. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103751 · Cited by 73 · cited 1×
“258 Recent studies have revealed the potential of apigenin to act as an immunomodulator, positioning it as a promising candidate for cancer therapy repurposing.”
BackgroundSystematic prediction of drug combinations based on clinical side-effects
Huang, H., Zhang, P., Qu, X. A., Sanseau, P., & Yang, L. (2014) · Scientific Reports · doi:10.1038/srep07160 · Cited by 73 · cited 1×
“29,30 Current computational methodologies, such as merging drug effects with clinical disease signatures and model systems that predict disease-modifying effects, are available for the selection of drug candidates suitable for drug repurposing in cancer.”
BackgroundSelf-citationShi, M., Yang, Z., Hu, M., Liu, D., Hu, Y., Qian, L., Zhang, W., Chen, H., Guo, L., Yu, M., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202364 · Cited by 73 · cited 1×
“328 In conclusion, β -adrenergic antagonists, repurposed as anticancer drugs, might be suitable candidates for combination therapies targeting disparate neoplastic processes.”
BackgroundTanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis
Ni, H., Ruan, G., Sun, C., Yang, X., Miao, Z., Li, J., Chen, Y., Qin, H., Liu, Y., Zheng, L., et al. (2022) · Environmental Toxicology · doi:10.1002/tox.23388 · Cited by 72 · cited 1×
“95 Interestingly, Lin et al. demonstrated that Tanshinone IIA might also induce necroptosis in human HCC by promoting the formation of a necrosomal complex composed of receptor-interacting protein 1 (RIP1)/RIP3.”
BackgroundThe Importance of Mitochondrial Pyruvate Carrier in Cancer Cell Metabolism and Tumorigenesis
Ruiz-Iglesias, A., & Mañes, S. (2021) · Cancers · doi:10.3390/cancers13071488 · Cited by 72 · cited 1×
“For instance, many types of cancers display dysregulation in cell metabolism, 389,390 and impaired apoptotic pathways.”
BackgroundMao, X., Zhang, X., Zheng, X., Chen, Y., Xuan, Z., & Huang, P. C. (2021) · Journal of Natural Medicines · doi:10.1007/s11418-021-01505-1 · Cited by 71 · cited 1×
“293 Although the antitumor properties of curcumin have been con fi rmed by multiple pre-clinical and clinical studies, its transition into mainstream cancer treatment has been limited by its subpar bioavailability.”
BackgroundEffects of soy containing diet and isoflavones on cytochrome P450 enzyme expression and activity
Ronis, M. J. J. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1206562 · Cited by 71 · cited 1×
“170 Notably, the median daily intake of iso fl avones for adults in Japan and China is estimated to be between 25 and 50 mg, which is signi fi cantly higher than the intake levels of Western females.”
BackgroundWang, M., Zhou, B., Cong, W., Zhang, M., Li, Z., Li, Y., Liang, S., Chen, K., Yang, D., & Wu, Z. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797605 · Cited by 71 · cited 1×
“343 Such modulations affect microbiota metabolism through regulation of the tryptophan pathways.”
BackgroundNath, J., Paul, R., Ghosh, S. K., Paul, J., Singha, B., & Debnath, N. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118189 · Cited by 71
Tai, L.-H., Zhang, J., Scott, K. J., de Souza, C. T., Alkayyal, A. A., Ananth, A. A., Sahi, S., Adair, R. A., Mahmoud, A. B., Sad, S., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0246 · Cited by 70
Mebendazole in Enterobiasis Radiochemical and Pilot Clinical Study in 1,278 Subjects
Brugmans, J. P. (1971) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1971.03190030039008 · Cited by 70 · cited 1×
“155 159 MBZ has been shown to potentially suppress tumor growth in various cancer cell lines and animal models through the inhibition of microtubule polymerization, a process that, when interrupted, can lead to the death of rapidly dividing cells.”
BackgroundRepurposing drugs in oncology: From candidate selection to clinical adoption
Pantziarka, P., Verbaanderd, C., Huys, I., Bouche, G., & Meheus, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.008 · Cited by 69
Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance
Ajmeera, D., & Ajumeera, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.12.013 · Cited by 68
Wang, C., Liu, B., Xu, X., Zhuang, B., Li, H., Yin, J., Cong, M., Xu, W., & Lu, A. (2016) · Oncotarget · doi:10.18632/oncotarget.7073 · Cited by 67 · cited 1×
“90 Furthermore, TPL has been shown to induce autophagy-mediated caspase-independent cell death in tumor cells.”
BackgroundSuppressing Receptor-Interacting Protein 140: a New Sight for Salidroside to Treat Cerebral Ischemia
Chen, T., Ma, Z., Zhu, L., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9521-7 · Cited by 67
Felgenhauer, J. L., Nieder, M. L., Krailo, M., Bernstein, M. L., Henry, D. W., Malkin, D. M., Baruchel, S., Chuba, P. J., Sailer, S. L., Brown, K., et al. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24328 · Cited by 64
Seo, Y., Kim, J., Park, S. J., Park, J. J., Cheon, J. H., Kim, W. H., & Kim, T. I. (2020) · Cancers · doi:10.3390/cancers12092554 · Cited by 64
Falk, G. W., Buttar, N. S., Foster, N. R., Ziegler, K. L. A., DeMars, C. J., Romero, Y., Marcon, N. E., Schnell, T., Corley, D. A., Sharma, P., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.044 · Cited by 64
Structure-based drug repositioning: Potential and limits
Adasme, M. F., Parisi, D., Sveshnikova, A. N., & Schroeder, M. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.010 · Cited by 64
Taccioli, C., Sorrentino, G., Zannini, A., Caroli, J., Beneventano, D., Anderlucci, L., Lolli, M., Bicciato, S., & Del Sal, G. (2015) · Oncotarget · doi:10.18632/oncotarget.5749 · Cited by 64
Human cancer stem cells are a target for cancer prevention using (−)-epigallocatechin gallate
Fujiki, H., Sueoka, E., Rawangkan, A., & Suganuma, M. (2017) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2515-2 · Cited by 64
Campbell, E. J., Dachs, G. U., Morrin, H. R., Davey, V. C., Robinson, B. A., & Vissers, M. C. M. (2019) · BMC Cancer · doi:10.1186/s12885-019-5503-x · Cited by 63 · cited 1×
“303 Thus, the vast amount of preclinical and clinical data currently available indicates that ascorbic acid may be a promising agent for therapeutic repurposing, particularly with respect to its applications in targeted therapy and dietary treatment.”
BackgroundSilk Particles as Carriers of Therapeutic Molecules for Cancer Treatment
Florczak, A., Grzechowiak, I., Deptuch, T., Kucharczyk, K., Kamińska, A., & Dams‐Kozlowska, H. (2020) · Materials · doi:10.3390/ma13214946 · Cited by 63 · cited 2×
“353,354 Given these attributes, SF is gaining traction as a potential material for drug delivery systems, and could therefore play a transformative role in treating a variety of diseases.”
BackgroundMulti-Responsive Silk Fibroin-Based Nanoparticles for Drug Delivery
Ma, Y., Canup, B. S. B., Tong, X., Dai, F., & Xiao, B. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.585077 · Cited by 63 · cited 1×
“353,354 Given these attributes, SF is gaining traction as a potential material for drug delivery systems, and could therefore play a transformative role in treating a variety of diseases.”
BackgroundWang, Z., McLoone, P., & Morrison, D. S. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.598 · Cited by 63
Externally Controlled Triggered-Release of Drug from PLGA Micro and Nanoparticles
Hua, X., Tan, S., Bandara, H. M. H. N., Fu, Y., Liu, S., & Smyth, H. D. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114271 · Cited by 62 · cited 1×
“350,351 This adaptability is particularly impactful when encapsulating drugs and elevating their targeted delivery, especially in oncology.”
BackgroundQuercetin-Mediated Apoptosis and Cellular Senescence in Human Colon Cancer
Özsoy, S., Becer, E., Kabadayı, H., Vatansever, H. S., & Yücecan, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200408082026 · Cited by 62 · cited 1×
“238 Furthermore, quercetin was found to promote senescence in glioma cells by inhibiting the activity of HDACs.”
BackgroundEvia-Viscarra, M. L., Rodea-Montero, E. R., Apolinar-Jiménez, E., Muñoz-Noriega, N., García-Morales, L. M., Leaños-Pérez, C., Figueroa-Barrón, M., Sánchez-Fierros, D., & Reyes-García, J. G. (2012) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem-2011-0469 · Cited by 62
Nanoparticles guided drug delivery and imaging in gastric cancer
Nagaraju, G. P., Srivani, G., Dariya, B., Chalikonda, G., Farran, B., Behera, S. K., Alam, A., & Kamal, M. A. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.006 · Cited by 62
Lee, J. A., Yoo, S.-Y., Oh, H. J., Jeong, S., Cho, N.-Y., Kang, G. H., & Kim, J. H. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02657-x · Cited by 61 · cited 1×
“337 Therefore, studies into the causal relationship between the tumor microbial microenvironment and the overall TME may provide novel insights that contribute to the development of new drug research within the era of precision medicine.”
BackgroundBientinesi, E., Lulli, M., Becatti, M., Ristori, S., Margheri, F., & Monti, D. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111689 · Cited by 61 · cited 1×
“240 The ability of cancer cells to exploit senescence as a defense mechanism against therapies necessitates innovative approaches.”
BackgroundAssembly, Annotation, and Integration of UNIGENE Clusters into the Human Genome Draft
Zhuo, D., Zhao, W. D., Wright, F. A., Yang, H.-Y., Wang, J.-P., Sears, R., Baer, T., Kwon, D.-H., Gordon, D., Gibbs, S., et al. (2001) · Genome Research · doi:10.1101/gr.164501 · Cited by 61
β blockers in hypertension and cardiovascular disease
Ong, H. T. (2007) · BMJ · doi:10.1136/bmj.39185.440382.47 · Cited by 61
Chen, M., Lu, J., Wei, W., Lv, Y., Zhang, X., Yao, Y., Wang, L., Ling, T., & Zou, X. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161198 · Cited by 61 · cited 1×
“…studies, indicating that potential downstream effectors, such as the dephosphorylation of low-density lipoprotein receptor-related protein 6 and the inhibition of WNT/ β -catenin 312 or PI3K/AKT/mTOR/HIF-1 α signaling pathways, 313 follow the inhibition of V-type H + ATPase by PPIs in GC cells.”
BackgroundManaging pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study
Samson, S. L., Gu, F., Feldt-Rasmussen, U., Zhang, S., Yu, Y., Witek, P., Kalra, P., Pedroncelli, A. M., Pultar, P., Jabbour, N., et al. (2021) · Pituitary · doi:10.1007/s11102-021-01161-4 · Cited by 60
Zhu, L.-Q., Zhang, L., Zhang, J., Chang, G.-L., Liu, G., Yu, D.-D., Yu, X.-M., Zhao, M.-S., & Ye, B. (2021) · Journal of Integrative Medicine · doi:10.1016/j.joim.2020.11.001 · Cited by 60 · cited 1×
“342 In addition to its direct anticancer effects, EVO has also been shown to temper in fl ammatory reactions and tumor-associated immune responses.”
BackgroundRaja-Khan, N., Kunselman, A. R., Hogeman, C. S., Stetter, C. M., Demers, L. M., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2010.11.040 · Cited by 60
Clarke, K., Adler, N., Agrawal, D., Bhakta, D., Sata, S. S., Singh, S., Gupta, A., Pahwa, A., Pherson, E., Sun, A., et al. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.09.010 · Cited by 59 · cited 1×
“308,309 Over the years, PPIs have been administered to billions of people worldwide and have shown a remarkable safety pro fi le even at high dosages.”
BackgroundRao, Y., Li, R., & Zhang, D. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4487-z · Cited by 58 · cited 1×
“18 In addition, arsenic trioxide (a poison) and all-trans retinoic acid (a metabolite of vitamin A) are examples of other chemical compounds 19 that were approved by the FDA in 2000 for the treatment of acute promyelocytic leukemia.”
BackgroundDesign, implementation and management of a web-based data entry system for ClinicalTrials.gov.
Gillen, J. E., Tse, T., Ide, N. C., & McCray, A. T. (2004) · PubMed · Cited by 58
Hubackova, S., Davidova, E., Boukalova, S., Kovarova, J., Bajzikova, M., Coelho, A., Terp, M. G., Ditzel, H. J., Rohlena, J., & Neuzil, J. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-2224-7 · Cited by 58 · cited 1×
“108 Furthermore, in a phase I clinical trial aimed at refractory multiple myeloma, le fl unomide displayed manageable side effects, with disease stabilization occurring in 9 of the 11 patients (NCT: NCT02509052).”
BackgroundKim, H.-J., Park, J.-M., Kim, J.-A., & Ko, B.-P. (2008) · Journal of Acupuncture and Meridian Studies · doi:10.1016/s2005-2901(09)60033-9 · Cited by 57
Vishwanathan, K., Dickinson, P. A., Bui, K., Cassier, P. A., Greystoke, A., Lisbon, E. A., Moreno, V., So, K., Thomas, K., Weilert, D. K., et al. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1035 · Cited by 56
Ladson, G., Dodson, W. C., Sweet, S. D., Archibong, A. E., Kunselman, A. R., Demers, L. M., Lee, P. A., Williams, N. I., Coney, P., & Legro, R. S. (2011) · Fertility and Sterility · doi:10.1016/j.fertnstert.2011.05.048 · Cited by 56
Segna, D., Brusselaers, N., Glaus, D., Krupka, N., & Misselwitz, B. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211051463 · Cited by 56
Statins: Perspectives in cancer therapeutics
Corcos, L., & Jossic-Corcos, C. L. (2013) · Digestive and Liver Disease · doi:10.1016/j.dld.2013.02.002 · Cited by 54
Bak, E. J., Park, H. G., Kim, J. M., Kim, J. M., Yoo, Y.-J., & Cha, J.-H. (2010) · International Journal of Obesity · doi:10.1038/ijo.2009.223 · Cited by 54 · cited 1×
“339,340 Recent studies have revealed a role for EVO in targeting the microbial microenvironment, which may provide potential anticancer bene fi ts in a spectrum of malignancies.”
BackgroundEvodiamine Inhibits Helicobacter pylori Growth and Helicobacter pylori-Induced Inflammation
Yang, J. Y., Kim, J.-B., Lee, P., & Kim, S.-H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073385 · Cited by 54 · cited 1×
“341 EVO appears to exert its protective effects against CRC through modulation of the gut microbiota and reduction of intestinal in fl ammation, potentially through inhibition of the IL6/STAT3/ P65 signaling pathway.”
BackgroundGuo, Q., Li, Q., Wang, J., Liu, M., Wang, Y., Chen, Z., Ye, Y., Guan, Q., & Zhou, Y. (2019) · Medicine · doi:10.1097/md.0000000000016234 · Cited by 53
Mebendazole Monotherapy and Long-Term Disease Control in Metastatic Adrenocortical Carcinoma
Dobrosotskaya, I. Y., Hammer, G. D., Schteingart, D. E., Maturen, K. E., & Worden, F. P. (2011) · Endocrine Practice · doi:10.4158/ep10390.cr · Cited by 53 · cited 1×
“164,165 Together, these fi ndings demonstrate the critical need to learn more about the therapeutic pro fi le of MBZ to ensure its safety in oncological applications and determine its ef fi cacy as a groundbreaking anticancer treatment.”
BackgroundKim, Y.-J., Perumalsamy, H., Markus, J., Balusamy, S. R., Wang, C., Kang, S. H., Lee, S., Park, S. Y., Kim, S., Castro-Aceituno, V., et al. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1541900 · Cited by 51 · cited 1×
“…system not only displayed increased cytotoxicity but also increased apoptotic rates within tumors compared to application of ginsenoside alone, 373 suggesting that metal nanoparticle-imbued repurposed drugs may have the ability to inhibit tumor proliferation and potentially induce regression…”
BackgroundWang, C. J., Li, D., Danielson, J. A., Zhang, E. H., Dong, Z., Miller, K. D., Li, L., Zhang, J.-T., & Liu, J.-Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.026 · Cited by 51
HAPPI-2: a Comprehensive and High-quality Map of Human Annotated and Predicted Protein Interactions
Chen, J. Y., Pandey, R., & Nguyen, T. M. (2017) · BMC Genomics · doi:10.1186/s12864-017-3512-1 · Cited by 51
Metformin and Cancer Stem Cells: Old Drug, New Targets
Bednar, F., & Simeone, D. M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-12-0026 · Cited by 51 · cited 2×
“190,191 196 Recent studies have indicated that metformin might exert direct anticancer effects on a range of tumor cells, including the elusive CSCs, 197,198 thereby highlighting the multifaceted impact of metformin on cancer cells, as well as its potential to reduce phenotypic plasticity.”
BackgroundEmodin Induced SREBP1-Dependent and SREBP1-Independent Apoptosis in Hepatocellular Carcinoma Cells
Yang, N., Li, C., Li, H., Liu, M., Cai, X., Cao, F., Feng, Y., Li, M., & Wang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00709 · Cited by 51 · cited 1×
“275 Furthermore, Xing et al. demonstrated that the cytotoxic effects of emodin on HepG2 cells were associated with disruptions in metabolic homeostasis including oxidative stress and imbalances in amino acids.”
BackgroundCao, W., Liu, J., Wang, L., Li, M., Verstegen, M. M. A., Yin, Y., Ma, B., Chen, K., Bolkestein, M., Sprengers, D., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgy129 · Cited by 50 · cited 5×
“95 Interestingly, Lin et al. demonstrated that Tanshinone IIA might also induce necroptosis in human HCC by promoting the formation of a necrosomal complex composed of receptor-interacting protein 1 (RIP1)/RIP3.”
BackgroundInfluentialCoombes, R. C., Tovey, H., Kilburn, L., Mansi, J., Palmieri, C., Bartlett, J., Hicks, J., Makris, A., Evans, A., Loibl, S., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2193 · Cited by 50
Papait, A., Stefani, F. R., Cargnoni, A., Magatti, M., Parolini, O., & Silini, A. R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00447 · Cited by 50 · cited 1×
“The TME contains various immune cells, such as helper T (Th) cells, 241 Tregs, 242 dendritic cells, 243 TAMs, 244 and mesenchymal stem cells (MSCs), 245 as well as fi broblastic stromal cells, including cancer-associated fi broblasts (CAFs), which surround tumor cells and are sustained by adjacent…”
BackgroundHart, T. D., Dider, S., Han, W., Xu, H., Zhao, Z., & Xie, L. (2016) · Scientific Reports · doi:10.1038/srep20441 · Cited by 50
Chak, A., Buttar, N. S., Foster, N. R., Seisler, D. K., Marcon, N. E., Schoen, R., Cruz-Correa, M. R., Falk, G. W., Sharma, P., Hur, C., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.08.040 · Cited by 48
(1976) · PubMed · Cited by 48
Brambati, A., Colosio, A., Zardoni, L., Galanti, L., & Liberi, G. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00166 · Cited by 47 · cited 1×
“…including germline or somatic defects in DNA repair, 166 oncogene-induced replication stress, 69 fl awed mitotic chromosome segregation, 167 clashes between replication and transcription machinery 168 or even as a consequence of genotoxic anticancer treatments, 169 is a crucial hallmark of cancer.”
BackgroundMarsh, C. A., Berent-Spillson, A., Love, T., Persad, C. C., Pop-Busui, R., Zubieta, J.-K., & Smith, Y. R. (2013) · Fertility and Sterility · doi:10.1016/j.fertnstert.2013.02.054 · Cited by 47
Ozbudak, I. H., Karaveli, S., Simsek, T., Erdogan, G., & Pestereli, E. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2007.11.028 · Cited by 46 · cited 1×
“300 Furthermore, ascorbic acid has been shown to induce a dose-dependent decrease in the expression of HIF-1 α and GLUT1, both identi fi ed as downstream targets of HIF-1, in thyroid cancer cells in vitro.”
BackgroundAnti-Cancer Effects of Emodin on HepG2 Cells as Revealed by 1H NMR Based Metabolic Profiling
Xing, Y.-X., Li, M.-H., Tao, L., Ruan, L.-Y., Hong, W., Chen, C., Zhao, W.-L., Xu, H., Chen, J.-F., & Wang, J.-S. (2018) · Journal of Proteome Research · doi:10.1021/acs.jproteome.8b00029 · Cited by 46
Telomerase: A prominent oncological target for development of chemotherapeutic agents
Vishwakarma, K., Dey, R., & Bhatt, H. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115121 · Cited by 46 · cited 1×
“135,136 In addition, human telomerase reverse transcriptase (hTERT) plays an integral role in cancer signaling pathways as a transcriptional regulator, orchestrating the activation of crucial genes that are vital for tumor proliferation and survival.”
BackgroundRepurposing the yellow fever vaccine for intratumoral immunotherapy
Aznar, M. A., Molina, C., Teijeira, A., Rodriguez, I., Azpilikueta, A., Garasa, S., Sanchez‐Paulete, A. R., Cordeiro, L., Etxeberria, I., Alvarez, M., et al. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910375 · Cited by 44 · cited 1×
“264 Intrigu-ingly, Tai et al. found that administering a single dose of the in fl uenza vaccine intramuscularly a day before surgery optimally activated NK cells in speci fi c murine models.”
BackgroundShah, S., Famta, P., Fernandes, V., Bagasariya, D., Charankumar, K., Khatri, D. K., Singh, S. B., & Srivastava, S. (2022) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2022.09.024 · Cited by 44 · cited 1×
“368 Similarly, Hatamipour et al. found that NIC-loaded nanoliposomes markedly inhibited the growth of CT26 colon cancer cells, leading to a pronounced delay in tumor progression and increased survival.”
Background(2018) · Europe PMC (PubMed Central) · doi:10.22034/apjcp.2018.19.9.2553 · Cited by 44 · cited 1×
“45 Finally, a 2019 research study demonstrated the predictive potential of PDOs for personalized medicine, using a biobank of PDOs sourced from cancer patients participating in phase I/II clinical trials.”
BackgroundTargeting cholesterol metabolism in Cancer: From molecular mechanisms to therapeutic implications
Lu, J., Chen, S., Bai, X., Liao, M., Qiu, Y., Zheng, L., & Yu, H. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115907 · Cited by 44
Baxevanis, A. D. (2002) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi0102s00 · Cited by 44
Aging and cancer epigenetics: Where do the paths fork?
Pérez, R. F., Tejedor, J. R., Fernández, A. F., & Fraga, M. F. (2022) · Aging Cell · doi:10.1111/acel.13709 · Cited by 44 · cited 1×
“229 – 231 For example, DOX-induced systemic senescence was found to promote metastasis in an orthotopic mouse model of breast cancer.”
BackgroundCisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer
Lin, X.-M., Li, S., Zhou, C., Li, R.-Z., Wang, H., Luo, W., Huang, Y.-S., Chen, L.-K., Cai, J.-L., Wang, T.-X., et al. (2019) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2019.105610 · Cited by 43 · cited 1×
“179 182 Celecoxib has been shown to enhance the ef fi cacy of BRAF/MEKi treatments in melanoma through suppression of the NF-κ B pathway.”
BackgroundThe microbiome and rise of early-onset cancers: knowledge gaps and research opportunities
Mima, K., Hamada, T., Inamura, K., Baba, H., Ugai, T., & Ogino, S. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2269623 · Cited by 43
Anti-Cancer Potential of Synthetic Oleanolic Acid Derivatives and Their Conjugates with NSAIDs
Baer‐Dubowska, W., Narożna, M., & Krajka‐Kuźniak, V. (2021) · Molecules · doi:10.3390/molecules26164957 · Cited by 43
Assessing the Hepatic Safety of Epigallocatechin Gallate (EGCG) in Reproductive-Aged Women
Siblini, H., Al-Hendy, A. A., Segars, J. H., González, F., Taylor, H. S., Singh, B., Flaminia, A., Flores, V. A., Christman, G. M., Huang, H., et al. (2023) · Nutrients · doi:10.3390/nu15020320 · Cited by 43
Self-citationAntiprotozoal Activity of Triazole Derivatives of Dehydroabietic Acid and Oleanolic Acid
Pertino, M., Vega, C., Rolón, M. S., et al. (2017) · Molecules · doi:10.3390/molecules22030369 · Cited by 43
Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells
Adami, B. S., Diz, F. M., Oliveira Gonçalves, G. P., Reghelin, C. K., Scherer, M., Dutra, A. P., Papaléo, R. M., de Oliveira, J. R., Morrone, F. B., Wieck, A., et al. (2021) · Micron · doi:10.1016/j.micron.2021.103152 · Cited by 42
Shepherd, D. M., Jahnke, H. K., White, W. L., & Little, A. S. (2017) · Journal of neurosurgery · doi:10.3171/2016.10.jns161355 · Cited by 42
Martinez, J. A., Chalasani, P., Thomson, C. A., Roe, D., Altbach, M., Galons, J.-P., Stopeck, A., Thompson, P. A., Villa-Guillen, D. E., & Chow, H.-H. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2551-3 · Cited by 41
Cooper, J. P., Storer, B. E., Granot, N., Gyurkocza, B., Sorror, M. L., Chauncey, T. R., Shizuru, J. A., Franke, G., Maris, M. B., Boyer, M. J., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.248187 · Cited by 41
Richter, A., Olbrich, C., Krause, M., Hoffmann, J., & Kissel, T. (2010) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2010.02.010 · Cited by 41
Knight, J. M., Kerswill, S. A., Hari, P., Cole, S. W., Logan, B. R., D’Souza, A., Shah, N. N., Horowitz, M. M., Stolley, M. R., Sloan, E. K., et al. (2018) · BMC Cancer · doi:10.1186/s12885-018-4509-0 · Cited by 40
Cited by
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 183
Applications of Artificial Intelligence in Drug Repurposing
Wan, Z., Sun, X., Li, Y., Chu, T., Hao, X., Cao, Y., & Zhang, P. (2025) · Advanced Science · doi:10.1002/advs.202411325 · Cited by 126
A review of the current trends in computational approaches in drug design and metabolism
Ouma, R. B. O., Ngari, S. M., & Kibet, J. K. (2024) · Discover Public Health · doi:10.1186/s12982-024-00229-3 · Cited by 95
“Similarly, bufulfone and chlorambucil which were initially developed as alkylating agents based on toxic chemical warfare agent mustard gas, have been repurposed for treating leukemia [55].”
Artificial Intelligence in Head and Neck Cancer: Innovations, Applications, and Future Directions
Pham, T. D., Teh, M., Chatzopoulou, D., Holmes, S., & Coulthard, P. (2024) · Current Oncology · doi:10.3390/curroncol31090389 · Cited by 88
“For instance, drugs initially developed for other cancers or diseases may exhibit potential efficacy against HNC, offering a faster and more cost-effective route to developing new treatments [156,157].”
BackgroundAn Open Access Database of Licensed Cancer Drugs
Pantziarka, P., Capistrano, R., Potter, A. D., Vandeborne, L., & Bouche, G. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.627574 · Cited by 70
Metadata
- Authors
- Xia, Y., Sun, M., Huang, H., & Jin, W.-L.
- Affiliations
- Johns Hopkins University (US)
- Guiyang Medical University (CN)
- Corresponding author
- Huang, Hai
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2024-04-19
- Volume
- 9
- Issue
- 1
- Pages
- 92-92
- ISSN
- 2059-3635 (ISSN-L)
- PMC
- PMC11026526
- OpenAlex
- W4394934376
- Cited by
- 443
- References
- 513
- Citations by year
- 2026: 168 · 2025: 214 · 2024: 60
- FWCI
- 12.35
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Signal Transduction and Targeted Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82060442)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- drug repurposing, cancer therapy, cancer hallmarks, tumor microenvironment, drug resistance, combination therapy, nanotechnology, topical drug delivery, anticancer agents, clinical translation
- MeSH terms
- Combined Modality Therapy, Humans, Neoplasms, Drug Delivery Systems, Treatment Outcome, Drug Repositioning, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.